Literature DB >> 8429238

Localization of 92-kDa type IV collagenase in human skin tumors: comparison with normal human fetal and adult skin.

T V Karelina1, G J Hruza, G I Goldberg, A Z Eisen.   

Abstract

To investigate the role of secreted metalloproteinases in the behavior of skin tumors we have studied immunoreactivity for 92-kDa type IV collagenase (92T4Cl) in benign tumors of sweat glands, basal cell carcinomas (BCC), baso-squamous cell carcinomas (BSCC), and squamous cell carcinomas (SCC). In all tumors, the enzyme was found in stromal cells, but not in tumor epithelium. 92T4Cl-positive cells contained the common leukocyte antigen HLe-1(CD45) and the polymorphonuclear leukocyte-specific antigen PMN-8C7. Only a few 92T4Cl-positive cells expressed either macrophage-specific Leu-M5 or eosinophil-specific cationic protein antigens. In benign sweat gland tumors, and in the majority of nodulocystic and adenoid BCCs, 92T4Cl-positive cells were relatively rare and no extracellular deposition of the enzyme was found. In the more aggressive tumors examined, SCCs, BSCC, recurrent, infiltrative, and morpheaform BCCs, 92T4Cl-positive cells were very abundant. In addition, a significant quantity of extracellular enzyme was deposited both within the extracellular matrix adjacent to the tumor nests and in their basement membrane zone. In normal adult skin only a few scattered 92T4Cl-containing cells were found in the dermis whereas in fetal skin, groups of 92T4Cl-positive, HLe-1-negative cells were present in the upper dermis. These observations suggest that in cutaneous tumors, extensive infiltration of 92T4Cl containing polymorphonuclear leukocytes and the extracellular deposition of the enzyme in the basement membrane zone are signs of more aggressive tumor behavior.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429238     DOI: 10.1111/1523-1747.ep12462791

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  9 in total

Review 1.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin.

Authors:  D C von Bredow; A E Cress; E W Howard; G T Bowden; R B Nagle
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

3.  Type IV collagenase in squamous cell and basal cell skin carcinomas.

Authors:  N Slade; J Pavelić; B Kurslin; K Pavelić
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

Review 4.  Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: clinical and fundamental applications.

Authors:  F A Auger; M Rouabhia; F Goulet; F Berthod; V Moulin; L Germain
Journal:  Med Biol Eng Comput       Date:  1998-11       Impact factor: 2.602

5.  Tumor cell contact mediated transcriptional activation of the fibroblast matrix metalloproteinase-9 gene: involvement of multiple transcription factors including Ets and an alternating purine-pyrimidine repeat.

Authors:  B P Himelstein; E J Lee; H Sato; M Seiki; R J Muschel
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

6.  Density-dependent induction of 92-kd type IV collagenase activity in cultures of A431 human epidermoid carcinoma cells.

Authors:  B Xie; C D Bucana; I J Fidler
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Immunolocalizations of human gelatinase (type IV collagenase, MMP-9) and TIMP (tissue inhibitor of metalloproteinases) in normal epidermis and some epidermal tumors.

Authors:  T Kobayashi; N Onoda; T Takagi; H Hori; S Hattori; Y Nagai; S Tajima; T Nishikawa
Journal:  Arch Dermatol Res       Date:  1996-05       Impact factor: 3.017

8.  Collagenolytic and gelatinolytic matrix metalloproteinases and their inhibitors in basal cell carcinoma of skin: comparison with normal skin.

Authors:  J Varani; Y Hattori; Y Chi; T Schmidt; P Perone; M E Zeigler; D J Fader; T M Johnson
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia.

Authors:  F C Hamdy; E J Fadlon; D Cottam; J Lawry; W Thurrell; P B Silcocks; J B Anderson; J L Williams; R C Rees
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.